Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GPR41 (Free fatty acid receptor 3), GPR43 (Free fatty acid receptor 2), and GPR109A (Hydroxycarboxylic acid receptor 2) are a group of G protein-coupled receptors that serve as primary sensors for microbial metabolites, specifically short-chain fatty acids (SCFAs) like acetate, propionate, and butyrate [Nature Reviews Drug Discovery, 2011]. These receptors are predominantly expressed on intestinal epithelial cells and various immune cells, including neutrophils, macrophages, and regulatory T cells, where they facilitate the communication between the gut microbiota and the host immune system [Science, 2013]. GPR41 and GPR43 are involved in regulating energy expenditure and the secretion of metabolic hormones such as glucagon-like peptide-1 (GLP-1), while GPR109A acts as a high-affinity receptor for niacin and a low-affinity receptor for butyrate to exert potent anti-inflammatory and tumor-suppressive effects in the colon [Immunity, 2014]. Dysregulation of these signaling pathways is strongly linked to the pathogenesis of inflammatory bowel diseases, metabolic syndrome, and colorectal cancer [Frontiers in Endocrinology, 2020]. Consequently, they are viewed as promising therapeutic targets for treating chronic inflammatory and metabolic disorders, although drug development is complicated by the need for tissue specificity and the management of side effects like niacin-induced flushing [Pharmacological Reviews, 2018].
Activation of GPR41, GPR43, and GPR109A triggers intracellular signaling through Gi/o and Gq proteins, leading to decreased cAMP levels and increased calcium mobilization, which modulates immune cell function and metabolic hormone release [Le Poul et al., 2003; Thangaraju et al., 2009].
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Free fatty acid receptor 3, Free fatty acid receptor 2, and Hydroxycarboxylic acid receptor 2 (GPR41, GPR43, and GPR109A).